vebreltinib

Vebreltinib (Chinese name: 伯瑞替尼, brand name 万比锐) is a highly selective, orally bioavailable small molecule inhibitor targeting the c-Met receptor tyrosine kinase (also known as hepatocyte growth factor receptor, HGFR). c-Met is implicated in tumorigenesis through gene amplification, activating mutations (notably MET exon 14 skipping mutations), and protein overexpression. Vebreltinib blocks aberrant c-Met signaling pathways involved in cell proliferation, survival, invasion, and metastasis. It has demonstrated significant clinical efficacy in patients with advanced or metastatic non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutations—including those with brain metastases—and has also been approved for the treatment of glioblastoma. The drug shows high objective response rates and disease control rates with a manageable safety profile; most adverse events are mild to moderate and controllable[2][5][6][8]. Vebreltinib was developed by Avistone/Beijing Purunao Biotechnology for China and by Apollomics for ex-China territories[7][9].

Brand names

万比锐

Other names

伯瑞替尼